Titre
The ANTENATAL multicentre study to predict postnatal renal outcome in fetuses with posterior urethral valves: objectives and design.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Buffin-Meyer, B.
Auteure/Auteur
Klein, J.
Auteure/Auteur
van der Zanden, LFM
Auteure/Auteur
Levtchenko, E.
Auteure/Auteur
Moulos, P.
Auteure/Auteur
Lounis, N.
Auteure/Auteur
Conte-Auriol, F.
Auteure/Auteur
Hindryckx, A.
Auteure/Auteur
Wühl, E.
Auteure/Auteur
Persico, N.
Auteure/Auteur
Oepkes, D.
Auteure/Auteur
Schreuder, M.F.
Auteure/Auteur
Tkaczyk, M.
Auteure/Auteur
Ariceta, G.
Auteure/Auteur
Fossum, M.
Auteure/Auteur
Parvex, P.
Auteure/Auteur
Feitz, W.
Auteure/Auteur
Olsen, H.
Auteure/Auteur
Montini, G.
Auteure/Auteur
Decramer, S.
Auteure/Auteur
Schanstra, J.P.
Auteure/Auteur
Contributrices/contributeurs
Hindryckx, A.
De Catte, L.
Vayssieres, C.
Sartor, A.
Groussolles, M.
Plard, C.
Guerby, P.
Connan, L.
Morin, M.
Simon, E.
Breaud, J.
Saliou, A.H.
De Parscau, L.
Jay, N.
Germouty, I.
Le Bouar, G.
Ryckewaert, A.
Manca-Pellissier, M.C.
Merrot, T.
Laurichesse, H.
Gallot, D.
Bessenay, L.
Bidat, L.
Boize, P.
Winer, N.
Allain-Launey, E.
Le Vaillant, C.
Prieur, F.
Lavocat, M.P.
Coatleven, F.
Debromez, E.
Harembat, J.
Llanas, B.
Favre, R.
Moog, R.
Zaloszyc, A.
Massardier, J.
Demede, D.
Perrotin, F.
Cloarec, S.
Vequeau-Goua, V.
Descombes, E.
Boulot, P.
Morin, D.
Fuchs, F.
Tenenbaum, J.
Ville, Y.
Blanc, T.
Heidet, L.
Paris, A.
Dobremez, E.
Froute, M.F.
Gondry, J.
Muszynski, C.
Haraux, E.
Lobelle, F.
Chevreau, J.
Rosenblatt, J.
Baudoin, V.
Deschenes, G.
Guigue, V.
Amblard, F.
Bourdat-Michel, G.
Wühl, E.
Schaefer, F.
Elsässer, M.
Persico, N.
Rossi, F.
Manzoni, G.
De Marco, E.A.
Montini, G.
Capone, V.
Caforio, L.
Zaccara, A.
Innocenzi, M.
Bagolan, P.
Capozza, N.
Castagnetti, M.
Mancini, M.
Oepkes, D.
van Scheltema, P.A.
Feitz, W.
Kortmann, B.
Schreuder, M.
Tkaczyk, M.
Stańczyk, M.
Szaflik, K.
Wojtera, J.
Krzeszowski, W.
Talar, T.
Pawłowska, B.
Fortecka-Piestrzeniewicz, K.
Olejniczak, D.
Ariceta, G.
Arevalo, S.
Rodo, C.
Fossum, M.
Lindgren, P.
Parvex, P.
Chehade, H.
Groupes de travail
ANTENATAL Consortium
Liens vers les personnes
Liens vers les unités
ISSN
2048-8505
Statut éditorial
Publié
Date de publication
2020-06
Volume
13
Numéro
3
Première page
371
Dernière page/numéro d’article
379
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Posterior urethral valves (PUV) account for 17% of paediatric end-stage renal disease. A major issue in the management of PUV is prenatal prediction of postnatal renal function. Fetal ultrasound and fetal urine biochemistry are currently employed for this prediction, but clearly lack precision. We previously developed a fetal urine peptide signature that predicted in utero with high precision postnatal renal function in fetuses with PUV. We describe here the objectives and design of the prospective international multicentre ANTENATAL (multicentre validation of a fetal urine peptidome-based classifier to predict postnatal renal function in posterior urethral valves) study, set up to validate this fetal urine peptide signature.
Participants will be PUV pregnancies enrolled from 2017 to 2021 and followed up until 2023 in >30 European centres endorsed and supported by European reference networks for rare urological disorders (ERN eUROGEN) and rare kidney diseases (ERN ERKNet). The endpoint will be renal/patient survival at 2 years postnatally. Assuming α = 0.05, 1-β = 0.8 and a mean prevalence of severe renal outcome in PUV individuals of 0.35, 400 patients need to be enrolled to validate the previously reported sensitivity and specificity of the peptide signature.
In this largest multicentre study of antenatally detected PUV, we anticipate bringing a novel tool to the clinic. Based on urinary peptides and potentially amended in the future with additional omics traits, this tool will be able to precisely quantify postnatal renal survival in PUV pregnancies. The main limitation of the employed approach is the need for specialized equipment.
Accurate risk assessment in the prenatal period should strongly improve the management of fetuses with PUV.
Participants will be PUV pregnancies enrolled from 2017 to 2021 and followed up until 2023 in >30 European centres endorsed and supported by European reference networks for rare urological disorders (ERN eUROGEN) and rare kidney diseases (ERN ERKNet). The endpoint will be renal/patient survival at 2 years postnatally. Assuming α = 0.05, 1-β = 0.8 and a mean prevalence of severe renal outcome in PUV individuals of 0.35, 400 patients need to be enrolled to validate the previously reported sensitivity and specificity of the peptide signature.
In this largest multicentre study of antenatally detected PUV, we anticipate bringing a novel tool to the clinic. Based on urinary peptides and potentially amended in the future with additional omics traits, this tool will be able to precisely quantify postnatal renal survival in PUV pregnancies. The main limitation of the employed approach is the need for specialized equipment.
Accurate risk assessment in the prenatal period should strongly improve the management of fetuses with PUV.
PID Serval
serval:BIB_E0EE73CAFD3B
PMID
Open Access
Oui
Date de création
2021-04-16T10:21:28.327Z
Date de création dans IRIS
2025-05-21T03:02:24Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
32699617_BIB_E0EE73CAFD3B.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by-nc/4.0
Taille
631.32 KB
Format
Adobe PDF
PID Serval
serval:BIB_E0EE73CAFD3B.P001
URN
urn:nbn:ch:serval-BIB_E0EE73CAFD3B2
Somme de contrôle
(MD5):9f4b7fd7c2492da743438f77d41a3856